Cargando…

Current drugs for HIV-1: from challenges to potential in HIV/AIDS

The human immunodeficiency virus (HIV) persists in latently infected CD4(+)T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yuan, Zong, Yanjun, Wang, Dongfeng, Chen, Junbing, Chen, Zhe-Sheng, Peng, Fujun, Liu, Zhijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637376/
https://www.ncbi.nlm.nih.gov/pubmed/37954841
http://dx.doi.org/10.3389/fphar.2023.1294966
_version_ 1785133387607965696
author Peng, Yuan
Zong, Yanjun
Wang, Dongfeng
Chen, Junbing
Chen, Zhe-Sheng
Peng, Fujun
Liu, Zhijun
author_facet Peng, Yuan
Zong, Yanjun
Wang, Dongfeng
Chen, Junbing
Chen, Zhe-Sheng
Peng, Fujun
Liu, Zhijun
author_sort Peng, Yuan
collection PubMed
description The human immunodeficiency virus (HIV) persists in latently infected CD4(+)T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS.
format Online
Article
Text
id pubmed-10637376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106373762023-11-11 Current drugs for HIV-1: from challenges to potential in HIV/AIDS Peng, Yuan Zong, Yanjun Wang, Dongfeng Chen, Junbing Chen, Zhe-Sheng Peng, Fujun Liu, Zhijun Front Pharmacol Pharmacology The human immunodeficiency virus (HIV) persists in latently infected CD4(+)T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS. Frontiers Media S.A. 2023-10-26 /pmc/articles/PMC10637376/ /pubmed/37954841 http://dx.doi.org/10.3389/fphar.2023.1294966 Text en Copyright © 2023 Peng, Zong, Wang, Chen, Chen, Peng and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Peng, Yuan
Zong, Yanjun
Wang, Dongfeng
Chen, Junbing
Chen, Zhe-Sheng
Peng, Fujun
Liu, Zhijun
Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title_full Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title_fullStr Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title_full_unstemmed Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title_short Current drugs for HIV-1: from challenges to potential in HIV/AIDS
title_sort current drugs for hiv-1: from challenges to potential in hiv/aids
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637376/
https://www.ncbi.nlm.nih.gov/pubmed/37954841
http://dx.doi.org/10.3389/fphar.2023.1294966
work_keys_str_mv AT pengyuan currentdrugsforhiv1fromchallengestopotentialinhivaids
AT zongyanjun currentdrugsforhiv1fromchallengestopotentialinhivaids
AT wangdongfeng currentdrugsforhiv1fromchallengestopotentialinhivaids
AT chenjunbing currentdrugsforhiv1fromchallengestopotentialinhivaids
AT chenzhesheng currentdrugsforhiv1fromchallengestopotentialinhivaids
AT pengfujun currentdrugsforhiv1fromchallengestopotentialinhivaids
AT liuzhijun currentdrugsforhiv1fromchallengestopotentialinhivaids